FT839 cell therapy for autoimmune diseases
Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a new cell therapy (FT839) designed to target and reset the immune system's B cells to help treat moderate to severe autoimmune diseases that haven't improved with standard treatments. It's an early-phase study, so the main goals are to see if it's safe and if it helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a moderate or severe autoimmune disease (such as lupus, rheumatoid arthritis, or vasculitis) that has not responded to at least two prior treatments.
- Your major organs (heart, lungs, liver, kidneys) must be functioning reasonably well to handle the treatment.
- You cannot be pregnant, nursing, or have a history of certain infections, cancers, or organ transplants.
- You must not have received anti-CD19 or anti-CD20 therapies within the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
This trial tests a new treatment called CAR-T cell therapy for people with severe autoimmune rheumatic diseases that have not improved with other treatments. The therapy uses your own immune cells, which are modified in a lab to attack the cells causing the disease, potentially reducing symptoms and improving quality of life.
This trial is testing whether a type of immune cell therapy called CAR-T cells can help people with severe autoimmune diseases that have not improved with standard treatments. It may offer a new option for conditions like lupus, Sjogren's syndrome, or vasculitis when other therapies have failed.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial is testing a new type of cell therapy called universal CAR-T cells combined with immunosuppressant drugs for people with hard-to-treat autoimmune diseases. The goal is to see if this approach is safe and can help reduce disease activity.
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
Hear when a new Idiopathic Inflammatory Myositis (IIM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.